Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Raw Materials (2022 - 2025)

Historic Raw Materials for InMed Pharmaceuticals (INM) over the last 4 years, with Q3 2025 value amounting to $172200.0.

  • InMed Pharmaceuticals' Raw Materials fell 3725.52% to $172200.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $172200.0, marking a year-over-year decrease of 3725.52%. This contributed to the annual value of $258300.0 for FY2025, which is 3069.4% down from last year.
  • As of Q3 2025, InMed Pharmaceuticals' Raw Materials stood at $172200.0, which was down 3725.52% from $258300.0 recorded in Q2 2025.
  • In the past 5 years, InMed Pharmaceuticals' Raw Materials registered a high of $387071.0 during Q1 2023, and its lowest value of $172200.0 during Q4 2024.
  • Its 4-year average for Raw Materials is $250874.9, with a median of $233518.5 in 2022.
  • Examining YoY changes over the last 5 years, InMed Pharmaceuticals' Raw Materials showed a top increase of 7854.76% in 2024 and a maximum decrease of 4923.41% in 2024.
  • Quarter analysis of 4 years shows InMed Pharmaceuticals' Raw Materials stood at $208737.0 in 2022, then changed by 0.0% to $208737.0 in 2023, then decreased by 17.5% to $172200.0 in 2024, then changed by 0.0% to $172200.0 in 2025.
  • Its Raw Materials stands at $172200.0 for Q3 2025, versus $258300.0 for Q2 2025 and $258300.0 for Q1 2025.